[CAS NO. 104746-04-5] Eslicarbazepine

Name: Eslicarbazepine
Brand: Arctom Scientific
SKU: AS061296

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [104746-04-5]

Distributor

Catalog

AS061296

Brand

Arctom Scientific

CAS

104746-04-5

DESCRIPTION [104746-04-5]

Overview

MDL	MFCD08460933
Molecular Weight	254.28
Molecular Formula	C15H14N2O2
SMILES	O=C(N)N1C2=CC=CC=C2C[C@@H](C3=CC=CC=C31)O

For research use only. We do not sell to patients.

Summary

Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

In Vivo

Eslicarbazepine is an anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile. Eslicarbazepine acetate is a prodrug for eslicarbazepine (S-licarbazepine), which is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel ^[1] ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01822678	Bial - Portela C S.A.	Bipolar I Disorder	December 2005	Phase 2
NCT00988429	Bial - Portela C S.A.\|Sunovion	Partial Epilepsy	December 2, 2008	Phase 3
NCT01124097	Bial - Portela C S.A.	Post Herpetic Neuralgia	September 2010	Phase 3
NCT01422720	Bial - Portela C S.A.	Epilepsy	April 2010	Phase 3
NCT01878578	Bial - Portela C S.A.	Epilepsy	November 2002	Phase 1
NCT01129960	Bial - Portela C S.A.	Painful Diabetic Neuropathy	November 2010	Phase 3
NCT00988156	Bial - Portela C S.A.	Partial Epilepsy in Children and Adolescents	December 7, 2007	Phase 3
NCT00987558	Bial - Portela C S.A.	Epilepsy	June 2009	Phase 1
NCT00971295	Bial - Portela C S.A.	Neuropathic Pain	October 2007	Phase 1
NCT01830400	Eisai Inc.	Partial Onset Seizures	April 2012
NCT01824602	Bial - Portela C S.A.	BIPOLAR I DISORDER	February 2006	Phase 2
NCT03108729	Sunovion	Epilepsy	July 6, 2017	Phase 3
NCT00910247	Sunovion	Epilepsy	August 2009	Phase 3
NCT03116321	Bial - Portela C S.A.	Epilepsy	December 3, 2016	Phase 1
NCT02283801	Bial - Portela C S.A.	Epilepsy	November 2006	Phase 1
NCT00957684	Bial - Portela C S.A.	Refractory Partial Epilepsy	July 2004	Phase 3
NCT00900237	Bial - Portela C S.A.	Partial Epilepsy	November 2008	Phase 1
NCT01527513	Bial - Portela C S.A.	Partial Epilepsy	August 2010	Phase 2
NCT00957047	Bial - Portela C S.A.	Partial Epilepsy	July 2004	Phase 3
NCT03116828	Sunovion	Epilepsy With Partial On-set Seizures	July 7, 2017	Phase 4
NCT02912364	Stanford University\|Sunovion	Epilepsy	July 2016	Phase 4
NCT01091662	Sunovion	Epilepsy	June 2010	Phase 3
NCT01587339	GlaxoSmithKline	Epilepsy	September 2010
NCT00957372	Bial - Portela C S.A.	Partial Epilepsy	December 2004	Phase 3
NCT00898560	Bial - Portela C S.A.	Partial Epilepsy	September 2008	Phase 1
NCT00866775	Sunovion	Epilepsy With Simple or Complex Partial Onset Seizures	April 2009	Phase 3
NCT01162460	Bial - Portela C S.A.	Epilepsy	December 2010	Phase 3
NCT00981227	Bial - Portela C S.A.	Postherpetic Neuralgia	November 2007	Phase 2
NCT00980746	Bial - Portela C S.A.	Painful Diabetic Neuropathy	November 2007	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 983.17 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9327 mL	19.6634 mL	39.3267 mL
5 mM	0.7865 mL	3.9327 mL	7.8653 mL
10 mM	0.3933 mL	1.9663 mL	3.9327 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (8.18 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (8.18 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (8.18 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-hydroxy-, (10S)-

5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-hydroxy-, (S)-

(10S)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide

CGP 13751

(S)-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide

Eslicarbazepine

(S)-Licarbazepine

Erelib

BIA 2-194

Stedesa

Pazzul

(S)-(+)-10,11-Dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide

(S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide